MaineCare will approve hepatitis C treatment PA requests for members who meet the following guidelines. This PA form will cover up to twelve weeks of therapy. Only a 14-day supply will be allowed for the 1st fill. Pages 1-6 list the various regimens and the clinical situations for which they will be considered medically necessary according to MaineCare criteria, as well as the required supporting documentation. The PA must be approved prior to the 1st dose. Documentation of adherence (viral load changes or progress notes with a documented compliance discussion with details on compliance to date) will be required for continuation of therapy beyond 12 weeks & must be submitted with the PA request prior to completing the third month of therapy. FDA approved pediatric formulations of direct acting antivirals (DAA) and DAA approved for pediatric use will be approved for those under the age of eighteen when used in accordance with current AASLD guidelines including for indication and age-prior authorization is still required prior to the first dose.

The following documentation must be submitted with initial request for consideration of approval:

- Active HCV infection verified by viral load within the last year
- Child-Turcotte-Pugh (CTP) Score: \[\quad\text{Date: } \quad\]
- HCV Genotype verified by lab
  - Genotype: (circle) 1a 1b 2 3 4 5 6
- Fibrosis score: \[\quad\text{Date: } \quad\]
- Method(s) used: \[\quad\]
- Patient is candidate for Simplified Treatment as described at hcvguidelines.org. Must meet ALL of the following:
  - No prior HCV treatment
  - No evidence of cirrhosis by clinical exam or lab.
  - Not pregnant
  - HIV negative
  - HBsAg negative
  - No prior liver transplant
  - No end-stage renal disease
    (ie. eGFR < 30 mL/min/m\(^2\))
- Sovaldi: Current medication list that does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John’s Wort, or tipranavir/ritonavir
- Harvoni: Current medication list that does NOT include: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John’s Wort, ritonavir, tipranavir, Stribild, Crestor, H2 receptor antagonists above the following daily doses: famotidine 80 mg, ranitidine/nizatidine 600 mg or cimetidine 1600 mg; or PPIs above the following daily doses: esomeprazole 20 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg or dexlansoprazole 60mg
- Zepatier: Current medication list does NOT include: carbamazepine, phenytoin, rifampin, St. John’s Wort, efavirenz, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine, nelfinavir, ketoconazole, bosentan, tacrolimus, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (disoproxil fumarate or alafenamide), modafinil, daily doses exceeding the following: atorvastatin 20 mg or rosuvastatin 10 mg
- Mavyret: Medication list does NOT include atazanavir or rifampin
- Vosevi: Medication list does NOT include rifampin

These drug interaction lists are NOT all inclusive. Providers are urged to check up to date lists or on line drug interaction sites such as: https://www.hep-druginteractions.org/checker.
<table>
<thead>
<tr>
<th>Genotype 1a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment naive, no cirrhosis</strong> → <strong>Regimen 1 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment naive, compensated cirrhosis, Child-Pugh A ONLY</strong> → <strong>Regimen 1 (HIV neg only)</strong> or 2 (only if HIV positive) or 5</td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin ONLY), not cirrhotic</strong> → <strong>Regimen 1 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin ONLY), compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin + NS3 protease inhibitor (telaprevir, boceprevir, simeprevir), no prior NS5A, no sofosbuvir), no cirrhosis</strong> → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin + NS3 protease inhibitor (telaprevir, boceprevir, simeprevir), no prior NS5A, no sofosbuvir), compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (Non-NS5A inhibitor, sofosbuvir-containing regimen), no cirrhosis</strong> → <strong>Regimen 2</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (Non-NS5A inhibitor, compensated cirrhosis, Child-Pugh A ONLY)</strong> → <strong>Regimen 2</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced, any NS5A inhibitor but NO NS3/4A protease inhibitor (prior therapy ONLY with daclatasvir+sofosbuvir, ledipasvir+sofosbuvir or sofosbuvir + velpatasvir), no cirrhosis or compensated cirrhosis, Child-Pugh A ONLY</strong> → <strong>Regimen 3 or 7</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced, any NS5A inhibitor (ledipasvir (Harvoni), velpatasvir (Epclusa/Vosevi), elbasvir (Zepatier), dasabuvir (Viekira), daclatasvir (Daklinza) including those given with a NS3/4A protease inhibitor, but NOT including glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), non-cirrhotic or compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 7</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, non-cirrhotic</strong> → <strong>Regimen 7</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 8</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 15</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis</strong> → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAA), no cirrhosis</strong> → <strong>Regimen 7</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAA), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative based line characteristics</strong> → <strong>Regimen 13</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis</strong> (Child-Pugh B and C only) → <strong>Regimen 9</strong></td>
</tr>
<tr>
<td><strong>Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis</strong> (Child-Pugh B and C only) → <strong>Regimen 10</strong></td>
</tr>
<tr>
<td><strong>Decompensated cirrhosis, no prior sofosbuvir or NS5A</strong> → <strong>Regimen 6</strong> (low dose ribavirin if Child-Pugh Class C)</td>
</tr>
<tr>
<td><strong>Decompensated cirrhosis, no prior sofosbuvir or NS5A, ribavirin ineligible</strong> → <strong>Regimen 4</strong></td>
</tr>
<tr>
<td><strong>Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A</strong> → <strong>Regimen 11</strong> (low dose ribavirin if Child-Pugh Class C)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotype 1b</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment naive, no cirrhosis</strong> → <strong>Regimen 1 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment naive, compensated cirrhosis, Child-Pugh A ONLY</strong> → <strong>Regimen 1 (HIV neg only)</strong> or 2 (only if HIV positive) or 5</td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin ONLY), no cirrhosis</strong> → <strong>Regimen 1 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin ONLY), compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin + NS3 protease inhibitor (telaprevir, boceprevir, simeprevir), no prior NS5A, no sofosbuvir), no cirrhosis</strong> → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (PEG-IFN + ribavirin + NS3 protease inhibitor (telaprevir, boceprevir, simeprevir), no prior NS5A, no sofosbuvir), compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (Non-NS5A inhibitor, sofosbuvir-containing regimen), no cirrhosis</strong> → <strong>Regimen 2 or 5</strong></td>
</tr>
<tr>
<td><strong>Treatment experienced (Non-NS5A inhibitor, sofosbuvir-containing regimen), with compensated cirrhosis</strong> (Child-Pugh A ONLY) → <strong>Regimen 2 or 5</strong></td>
</tr>
</tbody>
</table>
Treatment experienced, any NS5A inhibitor but NO NS3/4A protease inhibitor (prior therapy ONLY with daclatasvir+sofosbuvir, ledipasvir+sofosbuvir or sofosbuvir +velpatasvir), no cirrhosis or compensated cirrhosis, Child-Pugh A ONLY  →  Regimen 3 or 7

Treatment experienced, any NS5A inhibitor (ledipasvir (Harvoni), velpatasvir (Epclusa/Vosevi), elbasvir (Zepatier), dasabuvir (Viekira), pibrentasvir (Mavyret) and daclatasvir (Daklinza), including those given with a NS3/4A protease inhibitor but NOT including pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, non-cirrhotic or compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 7

Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, non-cirrhotic  →  Regimen 7

Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 8

Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 7

Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis  →  Regimen 2 or 5

Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14

Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis  →  Regimen 7

Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative based line characteristics  →  Regimen 13

Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only)  →  Regimen 9

Re-infection of allograft liver after transplant, treatment experienced, compensated cirrhosis (Child-Pugh B and C only)  →  Regimen 10

Decompensated cirrhosis, no prior sofosbuvir or NS5A  →  Regimen 6 (low dose ribavirin# if Child-Pugh Class C)

Decompensated cirrhosis, no prior sofosbuvir or NS5A, ribavirin ineligible**  →  Regimen 4

Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A  →  Regimen 11 (low dose ribavirin# if Child-Pugh Class C)

Genotype 2

Treatment naïve, no cirrhosis  →  Regimen 1 or 5

Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY  →  Regimen 1 (HIV neg only) or 2 (only if HIV positive) or 5

Treatment experienced (PEG-IFN + ribavirin), no cirrhosis  →  Regimen 1 or 5

Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 2 or 5

Treatment experienced (sofosbuvir + ribavirin), with or without cirrhosis  →  Regimen 2 or 5

Treatment experienced (direct acting antiviral, including NS5A inhibitors EXCEPT glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 7

Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis  →  Regimen 7

Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 8

Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 15

Decompensated cirrhosis, no prior sofosbuvir or NS5A failure  →  Regimen 6 or if RBV ineligible**ONLY→  Regimen 4

Decompensated cirrhosis, prior sofosbuvir or NS5A failure  →  Regimen 11 (low dose ribavirin# if Child-Pugh C)

Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis  →  Regimen 2 or 5

Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)  →  Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14

Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis  →  Regimen 7

Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative baseline characteristics  →  Regimen 13
- Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only) → **Regimen 9**
- Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B and C only) → **Regimen 10**

### Genotype 3
- Treatment naïve, no cirrhosis → **Regimen 1 or 5**
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY → **Regimen 1** (HIV neg only) or 2 (only if HIV positive) or 5 (Y93H negative) or 6 (Y93H positive)
- Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H neg → **Regimen 3 or 5**
- Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H positive → **Regimen 3 or 6**
- Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis, Child-Pugh A ONLY → **Regimen 3 or 6**
- Treatment experienced (sofosbuvir + ribavirin +/- PEG-IFN), with or without compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 3**
- Treatment experienced (direct acting antiviral, including NSSA inhibitors EXCEPT glecaprevir/pibrentasvir (Mavreyet) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 7** or if prior NSSA failure and cirrhosis → **Regimen 8**
- Treatment experienced, glecaprevir/pibrentasvir (Mavreyet) failures, no cirrhosis → **Regimen 7**
- Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 8**
- Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 15**
- Decompensated cirrhosis, no prior sofosbuvir or NSSA failure → **Regimen 6** (low dose ribavirin# if Child-Pugh C) or, if RBV ineligible ONLY** ** → **Regimen 4**
- Decompensated cirrhosis, prior sofosbuvir or NSSA failure → **Regimen 11** (low dose ribavirin# if Child-Pugh C)
- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis → **Regimen 2 or 5**
- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14**
- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis → **Regimen 7**
- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative baseline characteristics → **Regimen 13**
- Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only) → **Regimen 9**
- Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B and C only) → **Regimen 10**

### Genotype 4
- Treatment naïve, no cirrhosis → **Regimen 1 or 5**
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY → **Regimen 1** (HIV neg only) or 2 (only if HIV positive) or 5
- Treatment experienced (PEG-IFN + ribavirin), no cirrhosis → **Regimen 1 or 5**
- Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis, Child-Pugh A ONLY → **Regimen 2 or 5**
- Treatment experienced (any direct acting antiviral including NSSA EXCEPT glecaprevir/pibrentasvir (Mavreyet) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 7**
- Treatment experienced, glecaprevir/pibrentasvir (Mavreyet) failures, no cirrhosis → **Regimen 7**
- Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 8**
- Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY) → **Regimen 15**
- Decompensated cirrhosis, no prior sofosbuvir or NSSA failure → **Regimen 6** (low dose ribavirin# if Child-Pugh Class C)
- Decompensated cirrhosis, no prior sofosbuvir or NSSA, ribavirin ineligible** ** → **Regimen 4**
- Decompensated cirrhosis, prior treatment with sofosbuvir or NSSA → **Regimen 11** (low dose ribavirin# if Child-Pugh Class C)
- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis \(\rightarrow\) Regimen 2 or 5

- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14

- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis \(\rightarrow\) Regimen 7

- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative based line characteristics \(\rightarrow\) Regimen 13

- Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only) \(\rightarrow\) Regimen 9

- Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B and C only) \(\rightarrow\) Regimen 10

### Genotype 5

- Treatment naïve, no cirrhosis \(\rightarrow\) Regimen 1 or 5
- Treatment naïve, no cirrhosis, HIV positive \(\rightarrow\) Regimen 2 or 5
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY, HIV negative \(\rightarrow\) Regimen 1 or 5
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY, HIV positive \(\rightarrow\) Regimen 2 or 5
- Treatment experienced (PEG-IFN + ribavirin), without cirrhosis \(\rightarrow\) Regimen 1 or 5
- Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 2 or 5
- Treatment experienced (any DAA including NSSA EXCEPT glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with no or compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 7
- Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis \(\rightarrow\) Regimen 7
- Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 8
- Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 15
- Decompensated cirrhosis, no prior sofosbuvir or NSSA \(\rightarrow\) Regimen 6 (low dose ribavirin# if Child-Pugh Class C)
- Decompensated cirrhosis, no prior sofosbuvir or NSSA, ribavirin ineligible** \(\rightarrow\) Regimen 4
- Decompensated cirrhosis, prior treatment with sofosbuvir or NSSA \(\rightarrow\) Regimen 11 (low dose ribavirin# if Child-Pugh Class C)

- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis \(\rightarrow\) Regimen 2 or 5

- Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14

- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis \(\rightarrow\) Regimen 7

- Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative based line characteristics \(\rightarrow\) Regimen 13

- Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only) \(\rightarrow\) Regimen 9

- Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B and C only) \(\rightarrow\) Regimen 10

### Genotype 6

- Treatment naïve, no cirrhosis, HIV negative \(\rightarrow\) Regimen 1 or 5
- Treatment naïve, no cirrhosis, HIV positive \(\rightarrow\) Regimen 2 or 5
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY, HIV negative \(\rightarrow\) Regimen 1 or 5
- Treatment naïve, compensated cirrhosis, Child-Pugh A ONLY, HIV positive \(\rightarrow\) Regimen 2 or 5
- Treatment experienced (PEG-IFN + ribavirin), without cirrhosis \(\rightarrow\) Regimen 1 or 5
- Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 2 or 5
- Treatment experienced (any DAA including NSSA EXCEPT glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with no or compensated cirrhosis (Child-Pugh A ONLY) \(\rightarrow\) Regimen 7
<table>
<thead>
<tr>
<th>Condition</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis</td>
<td>Regimen 7</td>
</tr>
<tr>
<td>Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A ONLY)</td>
<td>Regimen 8</td>
</tr>
<tr>
<td>Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis (Child-Pugh A ONLY)</td>
<td>Regimen 15</td>
</tr>
<tr>
<td>Decompensated cirrhosis, no prior sofosbuvir or NS5A</td>
<td>Regimen 6 (low dose ribavirin# if Child-Pugh Class C)</td>
</tr>
<tr>
<td>Decompensated cirrhosis, no prior sofosbuvir or NS5A, ribavirin ineligible*</td>
<td>Regimen 4</td>
</tr>
<tr>
<td>Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A</td>
<td>Regimen 11 (low dose ribavirin# if Child-Pugh Class C)</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, no cirrhosis</td>
<td>Regimen 2 or 5</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, treatment naïve or experienced but with no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)</td>
<td>Regimen 2 or 5 OR, if multiple negative baseline characteristics 9 or 14</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), no cirrhosis</td>
<td>Regimen 7</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, previous treatment with direct acting antivirals (DAAs), compensated cirrhosis (Child-Pugh A ONLY) and/or multiple negative baseline characteristics</td>
<td>Regimen 13</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B and C only)</td>
<td>Regimen 9</td>
</tr>
<tr>
<td>Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B and C only)</td>
<td>Regimen 10</td>
</tr>
</tbody>
</table>

**REGIMENS:**

1. Mavyret (glecaprevir/pibrentasvir) 100/40 mg; three (3) tablets daily for 56 days (8 weeks) □
2. Mavyret (glecaprevir/pibrentasvir) 100/40 mg; three (3) tablets daily for 84 days (12 weeks) □
3. Mavyret (glecaprevir/pibrentasvir) 100/40 mg; three (3) tablets daily for 112 days (16 weeks) □
4. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily for 168 days (24 weeks) □
5. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily for 84 days (12 weeks) □
6. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily + weight-based ribavirin for 84 days (12 weeks) □
7. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) 400/100/100 mg, one tablet daily for 84 days (12 weeks) □
8. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) 400/100/100 mg, one tablet daily + weight-based ribavirin for 84 days (12 weeks) □
9. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily + low dose ribavirin# for 84 days (12 weeks) □
10. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily + low dose ribavirin# for 168 days (24 weeks) □
11. Epclusa (sofosbuvir/velpatasvir) 400/100 mg daily + weight-based ribavirin for 168 days (24 weeks) □
12. Mavyret (glecaprevir/pibrentasvir) 300/120 mg; three (3) tablets daily + weight-based ribavirin for 112 days (16 weeks) □
13. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) 400/100/100 mg, one tablet daily + low dose ribavirin# for 84 days (12 weeks) □
14. Mavyret (glecaprevir/pibrentasvir) 300/120 mg; three (3) tablets daily + low dose ribavirin# for 84 days (12 weeks) □
15. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) 400/100/100 mg, one tablet daily + weight-based ribavirin for 168 days (24 weeks) □

# low dose ribavirin = 600 mg/day and increase as tolerated
¥ Genotype 1a polymorphisms at amino acid positions 28, 30, 31, or 93
For ANY regimen that includes ribavirin

☐ For women of childbearing potential (and male patients with female partners of childbearing potential):
   ☐ Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment or within 6 months of stopping
   ☐ Agreement that partners will use two forms of effective contraception during treatment and for at least 6 months after stopping
   ☐ Verification that monthly pregnancy tests will be performed throughout treatment

☐ For ribavirin-ineligible**: (Patients with CrCl <50 ml/min (moderate or severe renal dysfunction, ESRD, HD) should have dosage reduced
   ☐ History of severe or unstable cardiac disease
   ☐ Pregnant women and men with pregnant partners
   ☐ Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)
   ☐ Hypersensitivity to ribavirin
   ☐ Baseline platelet count <70,000 cells/mm3
   ☐ ANC <1500 cells/mm3
   ☐ Hb <12 gm/dl in women or <13 g/dl in men
   ☐ Other: ________________________________

Pursuant to the MaineCare Benefits Manual, Chapter I, Section 1.16, The Department regards adequate clinical records as essential for the delivery of quality care, such comprehensive records are key documents for post payment review. Your authorization certifies that the above request is medically necessary, meets the MaineCare criteria for prior authorization, does not exceed the medical needs of the member and is supported in your medical records.

Provider Signature: ___________________________ Date of Submission: ______________________________

* MUST MATCH PROVIDER LISTED ABOVE